CorMedix Inc CRMD
- Market cap
- $608.0M
- P/E
- 3.3×
Follow CRMD
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.75 | 1.60 | 0.85 | 4.86 | 2.16 | 4.30 | 2.65 | 2.57 | 2.89 | 5.60 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 22.70 | 12.40 | 12.00 | 13.70 | 9.42 | 18.80 | 8.03 | 6.09 | 13.85 | 17.43 |
High Price
|
|||
| 14 | 14 | 22 | 30 | 35 | 30 | 40 | 83 | 65 | 191 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
Revenue/Emp
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 43 | 312 |
Revenue
|
|||
| (63.63%) | 65.11% | 7.68% | (31.77%) | 14.38% | 22.00% | 94.34% | — | 92.66% | 88.46% |
Gross Margin
|
|||
| (25) | (33) | (27) | (21) | (27) | (29) | (30) | (46) | (19) | 150 |
EBT
|
|||
| (10,996.70%) | (10,024.26%) | (6,242.35%) | (7,586.97%) | (11,370.03%) | (15,432.37%) | (46,310.86%) | 0.00% | (44.45%) | 48.13% |
EBT Margin
|
|||
| (25) | (33) | (27) | (16) | (22) | (28) | (30) | (46) | (18) | 163 |
Net Income
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 |
Depreciation
|
|||
| 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.74 | 4.33 |
Revenue/Sh
|
|||
| (3.25) | (3.00) | (1.50) | (1.80) | (0.77) | (0.75) | (0.74) | (0.91) | (0.30) | 2.25 |
Earnings/Sh
|
|||
| (2.93) | (2.59) | (1.33) | (0.62) | (0.77) | (0.56) | (0.60) | (0.75) | (0.86) | 2.43 |
Cash Flow/Sh
|
|||
| (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | (0.04) | (0.01) | (0.01) | 0.00 | (0.03) |
Capex/Sh
|
|||
| (2.94) | (2.61) | (1.33) | (0.62) | (0.77) | (0.60) | (0.61) | (0.76) | (0.86) | 2.40 |
Free CF/Sh
|
|||
| 2.35 | 0.65 | 0.28 | 0.98 | 1.55 | 1.67 | 1.37 | 1.38 | 1.44 | 5.63 |
Book Value/Sh
|
|||
| 8 | 11 | 18 | 24 | 29 | 38 | 40 | 51 | 59 | 72 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 5.26 |
PE Ratio
|
|||
| 289.71 | 88.72 | 267.37 | 620.64 | 887.19 | 897.28 | 2,574.09 | — | 10.96 | 2.69 |
PS Ratio
|
|||
| 3.64 | 4.06 | 23.29 | 7.44 | 4.80 | 2.73 | 3.06 | — | 5.63 | 2.07 |
PB Ratio
|
|||
| 198.96 | 51.82 | 240.22 | 519.95 | 696.40 | 558.04 | 1,683.43 | — | 9.79 | 2.68 |
EV/Sales
|
|||
| (2.00) | (0.59) | (4.35) | (9.76) | (7.54) | (4.72) | (4.48) | — | (8.39) | 4.83 |
EV/FCF
|
|||
| (22) | (29) | (24) | (15) | (22) | (21) | (24) | (38) | (51) | 175 |
Op' Cash Flow
|
|||
| 0 | 0 | 0 | 0 | 0 | (1) | 0 | 0 | 0 | (2) |
Capex
|
|||
| (22) | (29) | (24) | (15) | (22) | (23) | (25) | (39) | (51) | 173 |
FCF
|
|||
| 18 | 7 | 11 | 24 | 44 | 61 | 53 | 68 | 81 | 193 |
Working Cap'
|
|||
| — | — | 6 | 0 | 1 | 1 | 1 | — | — | 145 |
Total Debt
|
|||
| (20) | (12) | (12) | (29) | (46) | (65) | (58) | (76) | (52) | (3) |
Net Debt
|
|||
| 18 | 7 | 5 | 24 | 44 | 63 | 55 | 70 | 85 | 405 |
Sh' Equity
|
|||
| (83.53%) | (186.71%) | (166.23%) | (180.27%) | (55.92%) | (47.71%) | (45.35%) | (64.32%) | (17.85%) | 34.51% |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (42.38%) | 23.34% |
ROIC
|
|||
| (95.10%) | (264.01%) | (442.49%) | (304.66%) | (64.91%) | (52.72%) | (50.40%) | (74.02%) | (23.17%) | 66.56% |
ROE
|
|||
CorMedix Inc peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| INDP Indaptus Therapeutics, Inc. | $606.8M | 0.0× | Compare |
| PRME Prime Medicine, Inc. | $609.4M | 0.0× | Compare |
| MNPR Monopar Therapeutics Inc. | $602.8M | 0.0× | Compare |
| CTMX CytomX Therapeutics, Inc. | $599.2M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ALLO Allogene Therapeutics, Inc. | $594.2M | 0.0× | Compare |
| ALT Altimmune, Inc. | $593.3M | 0.0× | Compare |
| NGNE Neurogene Inc. | $625.4M | 0.0× | Compare |
| VALN Valneva SE Sponsored ADR | $589.8M | 65.3× | Compare |
CorMedix Inc (CRMD) key facts
- CorMedix Inc (CRMD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024.
- As of September 25, 2026, CRMD traded at $7.85, a market capitalization of $608.0 million.
- Return on equity was 66.6% and debt-to-equity 0.32.
CorMedix Inc (CRMD) Latest News
7 Sep
CorMedix tripled profits yet issued guidance showing little change from prior expectations. Tripled profits signal stronger results while flat guidance limits upside revisions to future outlook.
31 Aug
CorMedix Inc (CRMD) upgraded to Buy rating. Buy upgrade may lift short-term investor sentiment without altering company fundamentals.
20 Aug
CorMedix Inc (CRMD) released its Q2 2026 earnings call transcript covering quarterly financial results, operational updates and forward outlook. Earnings call content supplies critical financial metrics and guidance that frequently drive meaningful shifts in valuation and sentiment.
14 Aug
CRMD stock rose after Q2 earnings and sales beat expectations driven by DefenCath and Melinta gains. Q2 earnings beat improves near-term financials and sentiment yet represents routine quarterly development.
13 Aug
CorMedix Inc posted record Q2 2026 revenue and raised EBITDA guidance. Record revenue and raised EBITDA guidance signal stronger financial results that can materially lift stock trajectory and sentiment.
CorMedix CEO anticipates supplemental filing for fungal disease treatment by Q3. CRMD stock records best day in nearly 10 months after earnings beat. Expected Q3 filing advances core treatment while earnings beat fuels sharp stock gains and shifts company trajectory.
CorMedix Inc. held its Q2 2026 earnings call covering quarterly financial results, operational updates and forward guidance. Quarterly earnings calls typically deliver financial metrics and guidance that moderately influence near-term stock sentiment and valuation.
CorMedix Inc shared Q2 earnings call highlights covering financial results, operational updates and outlook. Q2 earnings updates and guidance can moderately shift near-term investor sentiment and stock trajectory.
CorMedix Inc reported second quarter 2026 financial results and provided a business update. Quarterly financial results and business updates typically deliver moderate influence on near-term market sentiment and performance without fundamentally shifting long-term trajectory.
30 Jun
CRMD stock outlook improves as DefenCath and Rezzayo expand growth paths for CorMedix Inc. DefenCath and Rezzayo expansions signal major growth trajectory shift for CorMedix.
CorMedix Inc (CRMD) growth story expands beyond DefenCath into new trends. Expansion beyond core DefenCath product into new trends points to moderate additional growth avenues without confirmed transformative details.
CorMedix Inc (CRMD) delivers strong growth while confronting new risks that prompt questions on whether its stock remains a buy. Discussion of growth alongside new risks points to moderate effects on CRMD financial trajectory and investor views.
17 Jun
CorMedix reported Q1 results and raised its outlook, indicating its stock could be undervalued by 27.8%. Q1 results combined with raised outlook signal major positive shift likely to boost stock performance and investor sentiment.
16 Jun
CorMedix raised 2026 guidance on DefenCath momentum, potentially altering its bull case. Raised 2026 guidance plus DefenCath momentum point to major shifts in financial outlook and market position.
13 Jun
CorMedix Inc. reported its Q1 2026 financial results. Quarterly earnings reports directly affect stock valuation and near-term investor sentiment.
8 Jun
U.S. Court of Appeals for the Federal Circuit affirms CorMedix Therapeutics victory in Minocin patent litigation. Affirmed patent win bolsters CorMedix IP protection and competitive stance for Minocin.
22 May
CorMedix plans REZZAYO expansion while preparing for an impending reimbursement shift affecting DefenCath. REZZAYO expansion and DefenCath reimbursement changes mark major strategic and regulatory moves likely to reshape CorMedix trajectory.
17 May
CorMedix reported a strong Q1 earnings beat and raised its full-year outlook, potentially reinforcing the bullish case for the stock. Q1 beat and raised outlook indicate materially stronger results and improved growth visibility.
16 May
CorMedix Inc reported strong Q1 2026 results and raised full-year guidance, triggering an updated valuation assessment for the stock. Strong quarterly results and raised guidance signal improved operational momentum and positive shifts in CorMedix financial trajectory.
15 May
CorMedix Inc (CRMD) beat Q1 earnings expectations driven by strong DefenCath momentum and raised full-year guidance. Earnings beat and raised guidance from DefenCath momentum signal major positive shift in financial trajectory and investor sentiment.
14 May
CorMedix Inc (CRMD) reported strong revenue growth and strategic advancements in Q1 2026 earnings call highlights. Strong revenue growth and strategic progress signal significant commercial success and positive trajectory shift.
CorMedix Inc. summarized its Q1 2026 earnings call, covering financial results, operational updates, product developments, and forward-looking guidance. Q1 2026 earnings call summary discloses financial performance and strategic updates that could significantly influence investor sentiment and stock trajectory.
CorMedix Inc (CRMD) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial results, pipeline progress, and guidance that can significantly sway investor sentiment and stock trajectory.
CorMedix Inc (CRMD) released Q1 earnings call highlights detailing financial results, pipeline updates, and strategic outlook. Q1 earnings highlights cover financial performance and business developments that could significantly sway investor sentiment and stock trajectory.
CorMedix Inc (CRMD) shares jumped after the company beat revenue expectations and raised its full-year guidance. Revenue beat and higher full-year guidance indicate improved financial performance, driving share price surge and positive investor sentiment.
CorMedix Inc (CRMD) reported Q1 earnings and revenues that beat analyst estimates. Beating Q1 earnings estimates signals strong financial performance and likely boosts investor sentiment and stock trajectory.
CorMedix Therapeutics reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business update moderately influence financial performance and investor sentiment.
11 May
CorMedix (CRMD) story shifts as analysts split on price targets ranging from US$13 to US$15. Split analyst targets of US$13–US$15 signal mixed but noticeable shifts in investor sentiment toward CorMedix (CRMD).
7 May
CorMedix Inc. (CRMD) earnings are expected to grow ahead of next week's release, highlighting key factors like revenue projections, EPS estimates, and analyst insights. Expected earnings growth can moderately influence financial performance and investor sentiment prior to the release.
27 Apr
CorMedix Therapeutics announced positive topline results from the Phase III ReSPECT trial evaluating REZZAYO® for prophylaxis of invasive fungal diseases in allogeneic hematopoietic stem cell transplantation patients. Positive Phase III topline results for REZZAYO in a high-need indication promise label expansion, transformative revenue growth, and major stock upside.